Subhechcha Ganguly 
In a decisive move, the Supreme Court of India has barred Baba Ramdev’s Patanjali Ayurved from advertising its products following accusations of disseminating misleading information. The decision comes in response to a petition filed by the Indian Medical Association (IMA) in August 2022, in protest against Patanjali’s advertisement titled “MISCONCEPTIONS SPREAD BY ALLOPATHY: SAVE YOURSELF AND THE COUNTRY FROM THE MISCONCEPTIONS SPREAD BY PHARMA AND MEDICAL INDUSTRY.”
The apex court’s bench, comprising Justices Hima Kohli and Ahsannudin Amanullah, expressed strong disapproval towards Patanjali’s actions, highlighting the breach of assurance made by the company in November 2023. Despite promising not to release statements attacking allopathic medicines, Patanjali continued its advertising campaign, prompting the court to intervene and impose the ban until further orders are issued.
The ruling underscores the gravity of the allegations against Patanjali, which stands accused of flouting ethical standards in its marketing practices. With public health and trust at stake, the court’s intervention serves as a stern warning to corporations against making unsubstantiated claims that could potentially endanger consumers and undermine the integrity of the medical profession.
